

Clinical Practice Guideline: Obesity/Overweight

Date of Implementation: June 19, 2014

Effective Date: May 21, 2026

Product: Specialty

GUIDELINES

Among portal of entry practitioners, screening for obesity and overweight using Body Mass Index (BMI) is considered best practice. Referrals for body fat measurement are also important, especially for individuals who have a high BMI and are highly active (engaging in more than 150 minutes of moderate or 75 minutes of vigorous physical activity per week).

Providing a direct intervention (e.g., lifestyle and/or dietary changes) for adult patients identified as having obesity or overweight, will depend upon the practitioner's education, training, experience, and scope of practice. In the absence of such a direct intervention, providing a referral intervention (e.g., to the patient's medical physician) is considered necessary. Measurements such as BMI and/or body fat percentage may be outside the education, training, experience, or scope of some practitioner types. In the context of best practices, for these practitioners, a level of awareness of risk factors and/or signs/symptoms that overweight/obesity is present and a subsequent referral for appropriate evaluation is necessary and within the purview of all.

INTRODUCTION

The impact of obesity and overweight on health is significant. Obesity is associated with health problems such as increased risk for coronary heart disease, stroke, type 2 diabetes, various types of cancer (e.g., liver, kidney, breast, endometrial, prostate, and colon), gallstones, and disability. Obesity is also associated with an increased risk for death, particularly among adults younger than 65 years. The leading causes of death among adults with obesity include ischemic heart disease, type 2 diabetes, respiratory diseases, and cancer.

As BMI increases above 25, the risk of developing chronic conditions such as coronary heart disease (CHD), hypertension, stroke, type 2 diabetes, and cancer of the colon, kidney, gallbladder, breast, and endometrium also rises. The probability of developing other conditions such as gall bladder disease, sleep apnea, and osteoarthritis of weight-bearing joints is higher in individuals with obesity and overweight. Obesity can adversely affect overall quality of life, as it may impair mobility, leading to limited functional and social activities, along with social stigmatization. Among individuals ≥ 65 years however, a BMI between 25 and 27 may be associated with reduced mortality. For example, a slightly

higher BMI in a person 65 years or older may help protect against osteoporosis (Winter et al., 2014). Further, obesity and overweight among children is being shown to produce similar manifestations as adults on the child's physical and psychological health including quality of life (Cuda and Censani, 2018). Additionally, the 15-year mortality risk among adults aged 20 – 49 is higher when body fat percentage is > 27% for men and >44% for women.

ASSESSING OBESITY

As appropriate to a practitioner's education, training, experience, and scope of practice, there are various techniques in use to measure obesity, including body mass index (BMI), bioelectrical impedance, dual-energy x-ray absorptiometry (DEXA), and total body water immersion and body fat percentage. BMI represents a calculation of body weight adjusted for height (weight in kilograms divided by height in meters squared) (USPSTF, 2018). Risk for adverse health effects increases linearly with BMI. However, increased musculature (e.g., with some athletes) increases BMI which negatively impacts the accuracy of this measure.

The U.S. Preventive Services Task Force (USPSTF) has designated measurement of BMI by the clinician as the appropriate screening method for obesity/overweight. There are numerous online BMI calculators including the National Institutes of Health's at http://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm.

- BMI of 25-29.9 kg/m² indicates overweight while
- BMI ≥ 30 kg/m² indicates obesity
 - Obesity is further differentiated into 3 classes:
 - I = BMI 30-34.9 kg/m²
 - II = BMI 35-39.9 kg/m²
 - III = BMI ≥ 40 kg/m²

Obesity in children is defined as a body mass index (BMI) at or above the 95th percentile of the CDC gender-specific BMI-for-age growth charts.

Another helpful measure in assessing health risks is central adiposity or waist circumference, which is associated with risk of cardiovascular disease, diabetes, and other conditions, independent of obesity. Central adiposity is measured by waist circumference (WC); men with a WC > 40 inches (102 cm) and women with a WC > 35 inches (88 cm) are at increased risk for cardiovascular disease. Because BMI does not assess body fat distribution, WC is a useful measure, as central adiposity is an indicator of health risk independent of body fat percentage or BMI. The following table summarizes the relationship of BMI and WC to health risks (Garvey et al., 2016). As with BMI, measuring central adiposity may be outside the scope for some practitioners. In such cases, one's clinical impression/awareness that overweight/obesity might be of issue is an appropriate reason for a referral intervention.

1 **Relationship of BMI and WC to Health Risks**

Description	BMI (kg/m ²)	Obesity class	Waist Circumference (WC) and Associated Health Risks	
			WC Men ≤ 40” or Women ≤ 35”	WC Men > 40” or Women > 35”
Underweight	<18.5			
Normal	18.5-24.9			
Overweight	25-29.9		Increased risk	High risk
Obese	30-34.9	I	High risk	Very high risk
	35-39.9	II	Very high risk	Very high risk
Extremely Obese	40+	III	Extremely high risk	Extremely high risk

2 https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi_dis.htm

3

4 The Lancet Diabetes & Endocrinology Commission (Rubino et al., 2025) provides a new
 5 comprehensive overview of the definition and diagnostic criteria for clinical obesity which
 6 has been endorsed by over 76 health organizations worldwide. It emphasizes that current
 7 BMI-based measures of obesity can both underestimate and overestimate adiposity,
 8 providing inadequate information about individual health. The Commission recommends
 9 that BMI should only be used as a surrogate measure of health risk at a population level,
 10 for epidemiological studies, or for screening purposes, rather than as an individual measure
 11 of health. Excess adiposity should be confirmed by 1) either direct measurement of body
 12 fat or; 2) at least one anthropometric criteria (e.g., waist circumference, waist-to-hip ratio
 13 or waist-to-height ratio) in addition to BMI or; 3) at least two anthropometric criteria
 14 regardless of BMI. Validated methods and cutoff points appropriate to age, gender, and
 15 ethnicity should be used for any anthropometric criteria used. The commission proposes a
 16 two-tier classification system. The first tier is preclinical obesity, defined as individuals
 17 who have excessive body fat but no related medical conditions but generally have an
 18 increased risk in developing clinical obesity. The second tier is clinical obesity which is
 19 defined as a chronic, systemic illness characterized by alterations in the function of tissues,
 20 organs, or the entire individual due to excess adiposity. This condition can lead to severe
 21 end-organ damage, causing life-altering and potentially life-threatening complications
 22 such as heart attack, stroke, and renal failure. People with clinical obesity should receive
 23 timely, evidence-based treatment aimed at improving or achieving remission of clinical
 24 manifestations and preventing progression to end-organ damage. Those with preclinical
 25 obesity should undergo health counseling, monitoring, and appropriate intervention to
 26 reduce the risk of developing clinical obesity and other obesity-related diseases.

27

28 The Commission also highlights the importance of addressing weight-based bias and
 29 stigma, which are major obstacles in efforts to effectively prevent and treat obesity.

1 **USPSTF Recommendation Levels:**

Grade	Definition	Suggestions for Practice
A	The USPSTF <i>recommends</i> the service. There is high certainty that the net benefit is substantial.	Offer or provide this service.
B	The USPSTF <i>recommends</i> the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.	Offer or provide this service.
C	The USPSTF recommends <i>selectively</i> offering or providing this service based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small.	Offer or provide this service for selected patients depending on circumstances.
D	The USPSTF recommends <i>against</i> the service. There is moderate or high certainty of either no net benefit or that the harms outweigh the benefits.	Discourage the use of this service.
I	The USPSTF concludes that the current evidence is <i>insufficient</i> to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.	If the service is offered, patients should understand the uncertainty about the balance of benefits and harms.

2

3 A comprehensive review of the USPSTF rating process can be found in the *Preventive*
4 *Care Services*(CPG 140 – S) clinical practice guideline or at the USPSTF website
5 ([https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-](https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-definitions)
6 [processes/grade-definitions](https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-definitions)).

7

8 **USPSTF Recommendations:**

9 **Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults:**
10 **Behavioral Interventions (2018)**

11 Grade B Recommendation: *The USPSTF recommends that clinicians offer or refer adults*
12 *with a body mass index (BMI) of 30 or higher (calculated as weight in kilograms divided*
13 *by height in meters squared) to intensive, multicomponent behavioral interventions.*

14

15 **High Body Mass Index in Children and Adolescents: Interventions (2024)**

16 Grade B Recommendation: *The USPSTF recommends that clinicians screen for obesity in*
17 *children and adolescents 6 years and older and provide or refer them to comprehensive,*
18 *intensive behavioral interventions.*

INTERVENTIONS

Counseling and Behavioral Interventions. “Counseling” refers to advice from the clinician to the patient to promote change. “Behavioral interventions” refers to strategies that assist people in acquiring skills, motivation, and support needed to change their health habits. The 5A’s (Ask, Advise, Assess, Assist, and Arrange) is a framework frequently used in clinical practice to guide behavioral interventions (Alexander et al., 2011).

Applied to weight management for individuals with obese/overweight.:

- Ask the patient about weight, nutrient intake, and physical activities.
- Advise with clear and impactful recommendations (e.g., related to comorbidities and the personalized health consequences of not losing weight).
- Assess the patient’s readiness to change their lifestyle (diet and exercise).
- Assist the patient by providing counseling and/or self-help materials (e.g., websites, organizations, contact information) to help them manage their weight.
- Arrange for follow up with the practitioner or another practitioner specializing in an area to help the patient (e.g., a qualified nutrition professional).

Some behavioral interventions to obesity treatment are based on Social Learning Theory (Bandura, 2004), with the assumption that eating, and exercise are learned behaviors and that by modifying them, body weight can be changed. Common behavioral strategies used in behavioral weight loss programs are detailed below.

- **Self-monitoring:** Recording behaviors associated with food consumption and physical activity.
- **Stimulus control:** Restricting environmental factors associated with inappropriate behaviors.
- **Contingency management:** Rewarding appropriate behaviors.
- **Changing behavior parameters:** Changing or altering behaviors.
- **Cognitive-behavior modification:** Changing thinking patterns related to target behavior.

The patient’s main health concerns should be addressed as the primary focus. The practitioner may integrate the discussion of weight management issues that may be affecting the patient’s physical or emotional health into the clinical dialogue.

Key Steps for Health Practitioners

- Identify at-risk individuals and help them understand that modest weight loss (5–10 percent) can lead to clinically important reductions in disease risk factors.
- Encourage individuals to adopt healthy lifestyle behaviors: healthy food choices, regular physical activity, reduce sedentary activities such as watching television or computer games.
- Monitor and treat potential health effects of overweight or obesity.

The USPSTF recommends that health care practitioners counsel adults about physical activity selectively, based on risk factors, rather than incorporate counseling into the care of all patients within the population. These recommendations are based on the health benefits of physical activity, rather than on the effectiveness of practitioner counseling to promote changes in physical activity or long-term health outcomes. See the *Physical Activity (CPG 181-S)* clinical practice guidelines for more information.

The USPSTF (2018) found that behavior-based weight-loss interventions with or without weight loss medications resulted in more weight loss than usual care conditions. The degree of weight loss observed with the behavior-based weight loss interventions in the current review is slightly smaller but consistent in magnitude with the 2011 review on this topic. As in the previous review, authors noted that weight loss interventions resulted in a decreased risk of developing diabetes, particularly among those with prediabetes, although the prevalence of other intermediate health outcomes was less well reported. Limited evidence exists regarding health outcomes associated with weight loss interventions. Weight loss medications, but not behavior-based interventions, were associated with higher rates of harms compared with control arms. Heterogeneity within each individual intervention arm confounded with differences in the populations, settings, and trial quality, making it difficult to disentangle which variables may be driving larger effects. Long-term weight and health outcomes data, as well as data on important subgroups (e.g., those who are older, nonwhite, or overweight) were lacking and should be a high priority for future study. The USPSTF (2017) recommendations on obesity in children and adolescents stated that evidence suggests that lifestyle-based weight loss interventions with 26 or more contact hours are likely to help reduce excess weight in children and adolescents; average effect sizes were relatively small and highly variable.

Pharmacotherapy. If utilized, weight management medications are typically meant to be used along with nutrition, exercise, and behavior management. More recent formulations and unique drug combinations have come on to the market, some are approved by the FDA for weight loss and others are being prescribed for off label use in weight loss. In randomized controlled trials (RCTs), older classes of drugs and these newer formulations have resulted in from 3 to 20% weight reduction over placebo, including in adolescents. Adverse effects may occur. Patients must consult with their primary treating practitioner for assistance with the appropriate use of medications as part of their weight management program. This would require a health care practitioner for whom prescriptions are within their scope of practice.

Surgery

According to National Institutes of Health (NIH), patients with a BMI >40 kg/m² or with a BMI ≥ 35 kg/m² who have not responded to other treatment and who have severe health complications may be considered as candidates for bariatric surgery. The surgical approach is either restrictive or malabsorptive; currently restrictive techniques predominate. In

patients with *extreme* obesity, bariatric surgery resulted in large and sustained weight reduction (10-159 kg/22-350 lb over 1-5 years) (McTigue et al., 2003). Adverse effects of bariatric surgery include wound infection, re-operation (for up to 25% of cases), vitamin deficiencies, diarrhea, hemorrhage, and death (postoperative mortality rate = 0.2%) (O'Brien et al., 2019).

Concerns over unknown *long-term* consequences of such surgical procedures also persist. The development of persistent and unfavorable surgical consequences (e.g., symptomatic cholelithiasis, band-related complications, and bowel obstruction) requiring additional surgery, and gastrointestinal issues (bleeding, infection) and nutritional deficiencies are additional long-term concerns. These metabolic and nutritional consequences require lifelong monitoring and micronutrient supplementation (Madura and DiBiase, 2012).

Over time, the reduction in surgical complications with the laparoscopic approach and other technical advancements, along with sustained improvements in weight loss and reductions in obesity-related comorbidities (e.g., diabetes, hypertension) have increased the use of bariatric surgery as a treatment option. Obesity management is best done as a multidisciplinary team approach and includes multiple evaluations (e.g., nutritional, exercise, behavioral health) prior to surgical consideration as well as post-surgical long-term care (Madura and DiBiase, 2012).

Non-surgical Bariatric Procedures

Another option for treatment of obesity are non-surgical bariatric procedures such as the implanted gastric balloon. The balloons are placed endoscopically on an outpatient basis. The types of procedures are an option for patients who have not been successful with weight loss through nutrition and exercise, but who are not candidates for surgery. Studies have demonstrated significantly increased weight loss with the implants vs. nutritional management and exercise alone with a good safety profile.

PRACTITIONER SCOPE AND TRAINING

Practitioners should practice only in the areas in which they are competent based on their education, training, and experience. Levels of education, experience, and proficiency may vary among individual practitioners. It is ethically and legally incumbent on a practitioner to determine where they have the knowledge and skills necessary to perform such services and whether the services are within their scope of practice.

It is best practice for the practitioner to appropriately render services to a patient only if they are trained, equally skilled, and adequately competent to deliver a service compared to others trained to perform the same procedure. If the service would be most competently delivered by another health care practitioner who has more skill and training, it would be best practice to refer the patient to the more expert practitioner.

Best practice can be defined as a clinical, scientific, or professional technique, method, or process that is typically evidence-based and consensus driven and is recognized by a majority of professionals in a particular field as more effective at delivering a particular outcome than any other practice (Joint Commission International Accreditation Standards for Hospitals, 2020).

Depending on the practitioner's scope of practice, training, and experience, a patient's condition and/or symptoms during examination or the course of treatment may indicate the need for referral to another practitioner or even emergency care. In such cases it is essential for the practitioner to refer the patient for appropriate co-management (e.g., to their primary care physician) or if immediate emergency care is warranted, to contact 911 as appropriate. See the *Managing Medical Emergencies (CPG 159 – S)* clinical practice guideline for information.

Publicly available resources for both practitioners and members can be found through the Centers for Disease Control and Prevention (CDC), United States Preventive Services Task Force (USPSTF), and the Obesity Medicine Association (OMA).

REFERENCES

- Alexander SC, Cox ME, Boling Turer CL, et al. Do the five A's work when physicians counsel about weight loss?. *Fam Med*. 2011;43(3):179-184
- Anderson J, Kushner R, et al. Overweight and Obesity Management for Primary Care Clinicians: Executive Summary. *Clin Diabetes*. 2023;41(1):85-89. Published January 2, 2023. <https://doi.org/10.2337/cd22-0082>
- Bandura A. Health promotion by social cognitive means. *Health Educ Behav*. 2004;31(2):143-164. <https://doi.org/10.1177/1090198104263660>
- Borrell LN, Samuel L. Body mass index categories and mortality risk in US adults: the effect of overweight and obesity on advancing death. *Am J Public Health*. 2014;104(3):512-519. doi:10.2105/AJPH.2013.301597
- Centers for Disease Control and Prevention. FastStats: Obesity and Overweight. National Center for Health Statistics. Reviewed March 6, 2026. Accessed March 31, 2026 from <https://www.cdc.gov/nchs/fastats/obesity-overweight.htm>
- Centers for Disease Control and Prevention. Obesity. Retrieved March 31, 2026 from <https://www.cdc.gov/obesity/index.html>

- 1 Cawley J, Biener A, Meyerhoefer C, et al. Direct medical costs of obesity in the United
2 States and the most populous states. *J Manag Care Spec Pharm*. 2021;27(3):354-366.
3 doi:10.18553/jmcp.2021.20410
4
- 5 Cuda SE, Censani M. Pediatric Obesity Algorithm: A Practical Approach to Obesity
6 Diagnosis and Management. *Front Pediatr*. 2019;6:431. Published 2019 Jan 23.
7 doi:10.3389/fped.2018.00431
8
- 9 Fryar, CD, Carroll MD, Afful J. Prevalence of Overweight, Obesity, and Severe Obesity
10 Among Children and Adolescents Aged 2 – 19 Years: United States, 1963 – 1965
11 Through 2017 – 2018. National Center for Health Statistics; 2020. Retrieved March 31,
12 2026 from [https://www.cdc.gov/nchs/data/hestat/obesity-child-17-18/obesity-](https://www.cdc.gov/nchs/data/hestat/obesity-child-17-18/obesity-child.htm)
13 [child.htm](https://www.cdc.gov/nchs/data/hestat/obesity-child-17-18/obesity-child.htm)
14
- 15 Garvey WT, Mechanick JI, Brett EM, et al. American Association Of Clinical
16 Endocrinologists And American College Of Endocrinology Comprehensive Clinical
17 Practice Guidelines For Medical Care Of Patients With Obesity. *Endocr Pract*.
18 2016;22 Suppl 3:1-203. doi:10.4158/EP161365.GL
19
- 20 Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity
21 Among Adults: United States, 2017–2018. *NCHS Data Brief*. 2020;(360):1-8
22
- 23 Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation
24 and Treatment of Children and Adolescents With Obesity. *Pediatrics*.
25 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640
26
- 27 Hasib A. Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current
28 Advances and Future Directions. *Clin Med Insights Endocrinol Diabetes*.
29 2020;13:1179551420905844. Published 2020 Feb 14.
30 doi:10.1177/1179551420905844
31
- 32 Iqbal J, Wu HX, Hu N, et al. Effect of glucagon-like peptide-1 receptor agonists on body
33 weight in adults with obesity without diabetes mellitus-a systematic review and meta-
34 analysis of randomized control trials. *Obes Rev*. 2022;23(6):e13435.
35 doi:10.1111/obr.13435
36
- 37 Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment
38 of Obesity. *N Engl J Med*. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
39
- 40 Joint Commission International. Joint Commission International Accreditation Standards
41 for Hospitals. 7th ed. Joint Commission Resources; 2020

- 1 Kim TY, Kim S, Schafer AL. Medical Management of the Postoperative Bariatric Surgery
2 Patient. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. South Dartmouth
3 (MA): MDTText.com, Inc.; August 24, 2020
4
- 5 LeBlanc ES, Patnode CD, Webber EM, Redmond N, Rushkin M, O'Connor EA.
6 Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-
7 Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic
8 Review for the US Preventive Services Task Force. JAMA. 2018;320(11):1172-1191.
9 doi:10.1001/jama.2018.7777
10
- 11 Madura JA and DiBiase JK. Quick fix or long-term cure? Pros and cons of bariatric
12 surgery. F1000 Med Reports 2012, 4:19
13
- 14 Mainous AG 3rd, Yin L, Wu V, et al. Body Mass Index vs Body Fat Percentage as a
15 Predictor of Mortality in Adults Aged 20-49 Years. *Ann Fam Med*. 2025;23(4):337-343.
16 Published 2025 Jul 28. doi:10.1370/afm.240330
17
- 18 Ndetan H, Evans MW Jr, Bae S, Felini M, Rupert R, Singh KP. The health care provider's
19 role and patient compliance to health promotion advice from the user's perspective:
20 analysis of the 2006 National Health Interview Survey data. J Manipulative Physiol
21 Ther. 2010;33(6):413-418. doi:10.1016/j.jmpt.2010.06.009
22
- 23 National Heart, Lung, and Blood Institute. Overweight and Obesity: Treatment. National
24 Institutes of Health. Published March 24, 2022. Retrieved March 31, 2026 from
25 <https://www.nhlbi.nih.gov/health/overweight-and-obesity/treatment>
26
- 27 National Library of Medicine. Body Mass Index. MedlinePlus. Updated July 23, 2024.
28 Retrieved March 31, 2026 from:
29 <http://www.nlm.nih.gov/medlineplus/ency/article/007196.htm>
30
- 31 O'Brien PE, Hindle A, Brennan L, et al. Long-Term Outcomes After Bariatric Surgery: a
32 Systematic Review and Meta-analysis of Weight Loss at 10 or More Years for All
33 Bariatric Procedures and a Single-Centre Review of 20-Year Outcomes After
34 Adjustable Gastric Banding. *Obes Surg*. 2019;29(1):3-14. doi:10.1007/s11695-018-
35 3525-0
36
- 37 Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized
38 controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. *Surg*
39 *Obes Relat Dis*. 2015;11(4):874-881. doi:10.1016/j.soard.2014.12.006

- 1 Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical
2 obesity [published correction appears in *Lancet Diabetes Endocrinol*. 2025
3 Mar;13(3):e6. doi: 10.1016/S2213-8587(25)00006-3.]. *Lancet Diabetes Endocrinol*.
4 2025;13(3):221-262. doi:10.1016/S2213-8587(24)00316-4
- 5
- 6 Sarma S, Palcu P. Weight loss between glucagon-like peptide-1 receptor agonists and
7 bariatric surgery in adults with obesity: A systematic review and meta-analysis. *Obesity*
8 (*Silver Spring*). 2022;30(11):2111-2121. doi:10.1002/oby.23563
- 9
- 10 US Preventive Services Task Force. Weight loss to prevent obesity-related morbidity and
11 mortality in adults: behavioral interventions. *JAMA*. 2018;320(11):1163-1171
- 12
- 13 US Preventive Services Task Force. High body mass index in children and adolescents:
14 interventions. *JAMA*. 2024;332(3). Published June 18, 2024
- 15
- 16 Warshaw H. The new weight management meds. *Today's Dietitian*. 2024;25(9):24.
17 <https://www.todaysdietitian.com/newarchives/1123p24.shtml>
- 18
- 19 Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in
20 Adolescents with Obesity. *N Engl J Med*. 2022;387(24):2245-2257.
21 doi:10.1056/NEJMoa2208601
- 22
- 23 Winter JE, MacInnis RJ, Wattanapenpaiboon N, Nowson CA. BMI and all-cause mortality
24 in older adults: a meta-analysis. *Am J Clin Nutr*. 2014;99(4):875-890.
25 doi:10.3945/ajcn.113.068122
- 26
- 27 Wolfe BM, Kvach E, Eckel RH. Treatment of obesity: weight loss and bariatric surgery.
28 *Circ Res*. 2016;118(11):1844-1855. doi:10.1161/CIRCRESAHA.116.307591